Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
158 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Oropharyngeal Cancer - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Pipeline Review, H1 2017, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape. Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 6 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively. Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Oropharyngeal Cancer - Overview Oropharyngeal Cancer - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Oropharyngeal Cancer - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Oropharyngeal Cancer - Companies Involved in Therapeutics Development Advaxis Inc AstraZeneca Plc Cell Medica Ltd Celldex Therapeutics Inc Immunovaccine Inc ISA Pharmaceuticals BV Merck & Co Inc Pfizer Inc PNP Therapeutics Inc Tessa Therapeutics Pte Ltd Oropharyngeal Cancer - Drug Profiles axalimogene filolisbac - Drug Profile Product Description Mechanism Of Action R&D Progress BMX-001 - Drug Profile Product Description Mechanism Of Action R&D Progress CDX-3379 - Drug Profile Product Description Mechanism Of Action R&D Progress CMD-004 - Drug Profile Product Description Mechanism Of Action R&D Progress DPXE-7 - Drug Profile Product Description Mechanism Of Action R&D Progress ganetespib - Drug Profile Product Description Mechanism Of Action R&D Progress gedatolisib - Drug Profile Product Description Mechanism Of Action R&D Progress gedeptin - Drug Profile Product Description Mechanism Of Action R&D Progress ISA-101 - Drug Profile Product Description Mechanism Of Action R&D Progress nimotuzumab - Drug Profile Product Description Mechanism Of Action R&D Progress olaparib - Drug Profile Product Description Mechanism Of Action R&D Progress palbociclib - Drug Profile Product Description Mechanism Of Action R&D Progress pembrolizumab - Drug Profile Product Description Mechanism Of Action R&D Progress PGV-001 - Drug Profile Product Description Mechanism Of Action R&D Progress TT-12 - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Oropharyngeal Cancer - Dormant Projects Oropharyngeal Cancer - Discontinued Products Oropharyngeal Cancer - Product Development Milestones Featured News & Press Releases Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company's Lm Technology™ Platform Sep 14, 2015: FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac in HPV-Associated Head and Neck Cancer Jun 09, 2015: U.S. FDA approves IND application for TT12 HP-VST to begin Phase I trial involving Adoptive T cell therapy on Oropharyngeal Cancer and Cervical Cancer Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Oropharyngeal Cancer, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Oropharyngeal Cancer - Pipeline by Advaxis Inc, H1 2017 Oropharyngeal Cancer - Pipeline by AstraZeneca Plc, H1 2017 Oropharyngeal Cancer - Pipeline by Cell Medica Ltd, H1 2017 Oropharyngeal Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017 Oropharyngeal Cancer - Pipeline by Immunovaccine Inc, H1 2017 Oropharyngeal Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2017 Oropharyngeal Cancer - Pipeline by Merck & Co Inc, H1 2017 Oropharyngeal Cancer - Pipeline by Pfizer Inc, H1 2017 Oropharyngeal Cancer - Pipeline by PNP Therapeutics Inc, H1 2017 Oropharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H1 2017 Oropharyngeal Cancer - Dormant Projects, H1 2017 Oropharyngeal Cancer - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.